Login Register
icon_bulk_orderBulk order Acrobiosystems for ChineseChinese
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
SARS-CoV-2 | CD24 | CD73 | Trimer | CD19 | PD-1
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Recombinant Proteins & Antibodies

  • VEGF: Cutting off tumor\\\'s feeding channel
COVID-19 R&D

The importance of N protein variants in antibody test and drug design

Have you noticed that NTD could be a pivotal player during infection?

One jab and you’re done! CanSino and Johnson & Johnson adenovirus vaccines receive regulatory approval.

A year later: What we know about SARS-CoV-2 infectivity and growing concerns of emerging variants

Immune Checkpoint Proteins

ACROBiosystems has developed an exclusive immune checkpoint protein collection， The consistency and excellent performance of our proteins are confirmed by a variety of assays.

CD3 Proteins

ACROBiosystems has developed a series of homogeneous CD3 proteins with good bioactivity. They are verified as 1:1 heterodimers by nonreductive electrophoresis and MALS as well.

Targets for ADCs

ACROBiosystems has developed a series of products with different species and tags for a variety of hot targets. It is suitable for immune, antibody screening, SPR, cell activity detection and other experiments, and all SPR&BLI protocols are available for free.

Targets of CAR-T Cell Therapy

We also supply difficult-to-express proteins such as BCMA, CD19, ROR1, and EGFRVIII.

Fc Receptor Proteins

ACROBiosystems offers a comprehensive collection of recombinant Fc receptor proteins, including their common variants, to help expedite your mAb development.

PE-labeled protein

ACROBiosystems has developed an exclusive collection of PE-labeled proteins by a proprietary site-specific conjugation technology, and these proteins are ideal for detecting CAR expression.

MABSOL® Biotinylated Proteins

The Mabsol biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.

VEGF Proteins

ACROBiosystems has developed a variety of VEGF proteins with different molecules, subtypes, species, and tags to help expedite your antibody drug development. All SPR&BLI protocols are available for free.

Reagents for vaccine development

ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.

SARS-CoV-2 proteins&kits

High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.

Reagents for COVID-19 diagnostics

ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.

SARS-CoV-2 Related Kit Products

ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.

Newly Added Products

Spike Mutants from SARS-CoV-2 Variant B.1.1.7

ACROBiosystems are going full steam ahead on developing a collection of recombinant antigens for emergency SARS-CoV-2 variants. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.

Learn more

Site-specific conjugated PE-labeled proteins

ACROBiosystems has developed an exclusive collection of PE-labeled proteins by a proprietary site-specific conjugation technology, and these proteins are ideal for detecting CAR expression.

Learn more

News Center

A year later: What we know about SARS-CoV-2 infectivity and growing concerns of emerging variants
2021/03/01
A year later: What we know about SARS-CoV-2 infectivity and growing concerns of emerging variants
It has been a year since the COVID-19 pandemic began and plethora of research into SARS-CoV-2 has led to development of vaccines and therapeutics. In this article, we review what we’ve known about SARS-CoV-2 and COVID-19, the developments in fighting the pandemic and the threat of emerging variants.
Learn more
ACROBiosystems Enables the Development of New Tools to Fight SARS-CoV-2
2021/02/10
ACROBiosystems Enables the Development of New Tools to Fight SARS-CoV-2
In December, 2019, a novel coronavirus hit the human population and caused a worldwide pandemic from which we have yet to recover. Even considering that the current vaccines will be successful, we are still in need of more tools and novel approaches to effectively fight back the evolving SARS-CoV-2
Learn more
Can aerosolized nanobodies be a gamechanger in the fight against COVID-19?
2021/01/27
Can aerosolized nanobodies be a gamechanger in the fight against COVID-19?
After the outbreak of SARS-CoV-2, researchers as well as biotech and pharma industry responded quickly to develop vaccines and therapeutics. Within less than a years’ time, breakthroughs in research and developments brought multiple vaccines and antibody therapeutics to hospitals at an unprecedented
Learn more

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap